Literature DB >> 27354670

A woman with a red eye from a carotid-cavernous sinus fistula.

Jonathan A Micieli1, Harleen Bedi2, Timo Krings2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27354670      PMCID: PMC5250517          DOI: 10.1503/cmaj.151029

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  7 in total

Review 1.  Intracranial dural arteriovenous fistulas: classification, imaging findings, and treatment.

Authors:  D Gandhi; J Chen; M Pearl; J Huang; J J Gemmete; S Kathuria
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-12       Impact factor: 3.825

Review 2.  Dural carotid-cavernous fistulas: epidemiology, clinical presentation, and management.

Authors:  Neil R Miller
Journal:  Neurosurg Clin N Am       Date:  2012-01       Impact factor: 2.509

3.  The validity of classification for the clinical presentation of intracranial dural arteriovenous fistulas.

Authors:  M A Davies; K TerBrugge; R Willinsky; T Coyne; J Saleh; M C Wallace
Journal:  J Neurosurg       Date:  1996-11       Impact factor: 5.115

4.  Arteriovenous malformation affecting the transverse dural venous sinus--an acquired lesion.

Authors:  O W Houser; J K Campbell; R J Campbell; T M Sundt
Journal:  Mayo Clin Proc       Date:  1979-10       Impact factor: 7.616

5.  Endovascular treatment of intracranial dural arteriovenous fistulas with cortical venous drainage: new management using Onyx.

Authors:  C Cognard; A C Januel; N A Silva; P Tall
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

Review 6.  Diagnosis and management of red eye in primary care.

Authors:  Holly Cronau; Ramana Reddy Kankanala; Thomas Mauger
Journal:  Am Fam Physician       Date:  2010-01-15       Impact factor: 3.292

7.  A proposed classification for spinal and cranial dural arteriovenous fistulous malformations and implications for treatment.

Authors:  J A Borden; J K Wu; W A Shucart
Journal:  J Neurosurg       Date:  1995-02       Impact factor: 5.115

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.